Anticholinergic vs long-acting β-Agonist in combination with inhaled corticosteroids in black adults with asthma: The BELT randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 16, 2015, Pages 1720-1730

  Wechsler, Michael E ^a,b   Yawn, Barbara P ^c   Fuhlbrigge, Anne L ^a   Pace, Wilson D ^d   Pencina, Michael J ^e,f   Doros, Gheorghe ^e,g   Kazani, Shamsah ^a,h   Raby, Benjamin A ^a   Lanzillotti, Jane ^e   Madison, Suzanne ^c   Israel, Elliot ^a   Ansari, Asif ⁱ   Raum, Donald ⁱ   Marthur, Manuja ⁱ   Avila, Pedro ^j   Bailey, James E ^k   Calhoun, William J ^l   Chang, Ku Lang ^m   Coto, Mario ⁿ   Davis, Cedrice ^o   Dawson, Rosalind ^p   Ferguson, M LaFrance ^p   Dransfield, Mark T ^q   Ferguson, Frances ^r   Greiner, Allen ^s   Jingo, Ahmad ^t   Pankey, William ^u   Schear, Martin ^v   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c OLMSTED MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g BOSTON UNIVERSITY   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

ⁱ Montefiore Medical Group Bronx East   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF TENNESSEE   (United States)

^l UNIVERSITY OF TEXAS   (United States)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ Coto and Assoc ^*  (United States)

^o Urban Family Practice   (United States)

^p Beaufort Jasper Hampton Comprehensive Health Services   (United States)

^q UNIVERSITY OF ALABAMA   (United States)

^r Albany Area Primary Health Care   (United States)

^s UNIVERSITY OF KANSAS   (United States)

^t RST Data Research   (United States)

^u Brigham and Women's Hospital ^*  (United States)

^v Hospice of Dayton   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INHALED CORTICOSTEROID; LONG ACTING BETA AGONIST; LONG ACTING DRUG; MOMETASONE FUROATE; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; ADRB2 PROTEIN, HUMAN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL FUMARATE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; SALBUTAMOL; SALMETEROL XINAFOATE; SCOPOLAMINE DERIVATIVE;

ADRB2 GENE; ADULT; ALLELE; ARTICLE; ASTHMA; BLACK PERSON; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNITED STATES; AFRICAN AMERICAN; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; ETHNOLOGY; FORCED EXPIRATORY FLOW; GENETICS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AFRICAN AMERICANS; ALBUTEROL; ASTHMA; CHOLINERGIC ANTAGONISTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY FLOW RATES; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, BETA-2; SALMETEROL XINAFOATE; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE;

EID: 84945289554     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.13277     Document Type: Article

References (34)

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007; 120(5 suppl): S94-S138.
2. 2-agonists to inhaled corticosteroids vs same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;(5): CD005535.
3. von Mutius E, Drazen JM. Choosing asthma step-up care. N Engl J Med. 2010; 362(11): 1042-1043.
4. Drazen JM, O'Byrne PM. Risks of long-acting β-agonists in achieving asthma control. N Engl J Med. 2009; 360(16): 1671-1672.
5. Peters J. ACP Journal Club: β-agonists increase asthma-related intubations and deaths in patients with asthma. Ann Intern Med. 2010; 153(6): JC3-JC5.
6. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129 (1): 15-26.
7. Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin. 2008; 24(6): 1669-1682.
8. Wechsler ME, Castro M, Lehman E, et al.; NHLBI Asthma Clinical Research Network. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med. 2011; 184(11): 1247-1253.
9. Spector SL, Martin UJ, Uryniak T, O'Brien CD. Budesonide/formoterol pressurized metered-dose inhaler vs budesonide: a randomized controlled trial in black patients with asthma. J Asthma. 2012; 49 (1): 70-77.
10. Israel E, Chinchilli VM, Ford JG, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004; 364(9444): 1505-1512.
11. Lipworth B. β-Adrenoceptor genotype and bronchoprotective subsensitivity with long-acting β-agonists in asthma. Am J Respir Crit Care Med. 2013; 188(12): 1386-1387.
12. Wechsler ME, Lehman E, Lazarus SC, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006; 173(5): 519-526.
13. 2-agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009; 374(9703): 1754-1764.
14. Peters SP, Kunselman SJ, Icitovic N, et al.; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010; 363(18): 1715-1726.
15. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multi-attribute Asthma Symptom Utility Index. Chest. 1998; 114(4): 998-1007.
16. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14(4): 902-907.
17. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993; 147(4): 832-838.
18. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992; 47(2): 76-83.
19. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994; 47(1): 81-87.
20. Sullivan SD, Liljas B, Buxton M, et al.; START Steering Committee. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. Control Clin Trials. 2001; 22(4): 420-437.
21. Yawn BMS, Bertram S, Pace W, et al. Automated patient and medication payment method for clinical trials. Open Access J Clin Trials. 2013; 5: 23-31. doi: 10.2147/OAJCT.S38489.
22. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997; 100(12): 3184-3188.
23. Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of 3 shortened versions of the asthma control questionnaire. Respir Med. 2005; 99(5): 553-558.
24. Bime C, Wei CY, Holbrook JT, Sockrider MM, Revicki DA, Wise RA. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol. 2012; 130(5): 1078-1084.
25. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012; 367(14): 1355-1360.
26. 2-agonist therapy: a pharmacogenetic analysis of 2 randomised studies. Lancet. 2007; 370(9605): 2118-2125.
27. 2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006; 118 (4): 809-816.
28. Rabe KF, Fabbri LM, Israel E, et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med. 2014; 2(1): 44-53.
29. Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during long-acting β-agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med. 2014; 2(3): 204-213.
30. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011; 364(26): 2473-2475.
31. US Food and Drug Administration. FDA Drug Safety Communication: FDA requires postmarket safety trials for long-acting β-agonists (LABAs). http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm. Accessed October 6, 2015.
32. Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States, 2001-2010. Vital Health Stat 3. 2012;(35): 1-58.
33. Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium vs salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013; 132 (5): 1068-1074.e1.
34. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015; 45(2): 396-407.